DEA Has 40,000 Comments and No Deadline — The Cannabis Rescheduling Clock Is Ticking Toward Late 2026

The public comment period closed last month. Now comes the part nobody can rush.

The Drug Enforcement Administration closed its public comment window on cannabis rescheduling in early March, ending a process that drew more than 40,000 submissions from patients, operators, researchers, advocacy groups, and opponents. What happens next is largely invisible — and entirely within the DEA’s discretion.

No vote. No announcement date. No external pressure that compels the agency to move. A final rule is expected sometime in late 2026, but that estimate carries no legal weight.

Here’s what’s actually at stake, who it affects, and why the pace of this thing matters as much as the outcome.

What This Actually Does

The DEA proposal would move cannabis from Schedule I — the same federal classification as heroin, reserved for substances with “no accepted medical use” — to Schedule III, which includes drugs like ketamine and anabolic steroids.

This would not legalize cannabis federally. Possession, sale, and distribution would remain federally prohibited outside of state-licensed structures. What it would do is trigger a cascade of downstream changes that matter enormously to the people living and working in the cannabis economy today.

The most immediate: 280E elimination. Under current law, cannabis businesses cannot deduct ordinary business expenses — payroll, rent, cost of goods — because they’re trafficking a Schedule I substance. The effective tax rate for many multi-state operators runs between 70–80% of gross profit. Reclassification ends that. Operators would suddenly be taxed like normal companies. For the industry’s larger players, this could add tens of millions of dollars back to the balance sheet in year one.

The second: research access. Schedule I restrictions have made clinical research on cannabis extraordinarily difficult — researchers need DEA approval to work with Schedule I substances, and supply pipelines are limited and slow. Schedule III status opens the door significantly. That matters for veterans pursuing VA coverage, for states trying to update their medical programs, and for the broader legitimacy argument that cannabis advocates have been making for decades.

What it does not do: unlock banking. The SAFE Banking Act — which would protect financial institutions that serve state-licensed cannabis businesses — is a separate legislative battle, still stalled in Congress. Rescheduling alone won’t convince a national bank to open accounts for a dispensary. That fight continues on a different track.

Who It Affects

State-licensed cannabis businesses face the most direct impact. The 280E burden has been quietly strangling balance sheets for years — profitable on paper, brutal in practice. For smaller operators and social equity licensees, that tax overhang has been an existential pressure, not just a financial inconvenience.

Medical patients — an estimated 4+ million registered across state programs — would see expanded research access over time, though not immediate changes to their day-to-day access. VA cannabis policy, still frozen under federal prohibition, may begin to shift once rescheduling removes the Schedule I designation.

Researchers and academic institutions currently sitting on stalled cannabis study protocols would gain a cleaner regulatory path. Universities that have avoided cannabis research due to institutional risk could begin to engage.

Recreational consumers in the 24+ adult-use states would feel little direct change — their state laws don’t hinge on federal scheduling. But the symbolic weight matters: Schedule III removes the federal government’s formal claim that cannabis has no medical value.

The Direction

This is expansion — a narrowing of federal prohibition for the first time in the DEA’s history. It doesn’t close the contradiction between federal law and the 40+ states that have legalized in some form, but it’s movement in the direction of resolution rather than entrenchment.

It’s worth noting that this process was not DEA-initiated. The Biden HHS formally recommended rescheduling in 2023 after a review requested by the administration. The DEA, which has twice rejected rescheduling petitions in prior decades, is now effectively implementing a directive from the executive branch. Whether the current administration continues to apply that pressure — or lets the rule-making clock run out — is the central uncertainty.

What Happens Next

The DEA’s review process is not publicly time-stamped. Agency reviewers are working through the comment record — 40,000 submissions is substantial — before drafting a final rule. Once drafted, that rule would face an additional review period, potential legal challenges from opponents, and final publication in the Federal Register.

The realistic window for a final rule is late 2026 at the earliest. Some analysts have moved that estimate into early 2027, particularly if the administration deprioritizes the rulemaking or if legal challenges begin before the rule is finalized.

There is no scheduled vote. There is no committee hearing. The next public milestone will be the final rule itself.

Who’s Behind This

The Biden HHS initiated this process with its 2023 recommendation — the first time a federal health agency formally endorsed rescheduling. That recommendation set the DEA review in motion.

The DEA now holds the pen. The agency has resisted rescheduling petitions twice before — in 2001 and 2016 — citing insufficient medical evidence. The legal and scientific landscape has shifted substantially since then, and the HHS recommendation carries political weight that prior petitions did not. That said, the DEA is not a rubber stamp, and agency discretion at the final rule stage is real.

Congressional cannabis advocates — led in recent sessions by figures like Rep. Earl Blumenauer (D-OR) and Sen. Ron Wyden (D-OR) — have pushed for full descheduling rather than rescheduling, arguing that Schedule III still leaves too much federal prohibition in place. Their criticism of the current process is that it doesn’t go far enough, not that it goes too far. Their leverage over the DEA’s rulemaking is limited.

Opponents have been more visible in the comment period than in past cycles. Some law enforcement groups, parent organizations, and anti-legalization advocates submitted comments arguing that rescheduling sends the wrong message and that the scientific evidence for medical benefit is overstated. These submissions will be part of the administrative record the DEA must address in its final rule — they cannot simply be ignored.

Cannabis industry trade groups — including the National Cannabis Industry Association and the U.S. Cannabis Council — submitted detailed pro-rescheduling comments focused primarily on 280E relief and research access. Their argument is economic and practical: Schedule III doesn’t legalize anything, it just stops punishing people for participating in a legal state activity.

The Bottom Line

A final rule is coming. The question is when, and whether the current administration maintains the political will to move it across the finish line before the calendar creates new obstacles.

For operators, 280E relief is real money. For patients, expanded research access is long-overdue legitimacy. For the broader federal policy picture, Schedule III is a directional signal — not a destination.

The DEA has 40,000 comments and no statutory deadline. That’s not a process designed for urgency.

Ethan Vale covers federal cannabis policy for CannabisInquirer.com.